Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.

Donaldson, Alana R; Shetty, Shashirekha; Wang, Zhen; Rivera, Christine L; Portier, Bryce P; Budd, G Thomas; Downs-Kelly, Erinn; Lanigan, Christopher P; Calhoun, Benjamin C

Donaldson, Alana R; Shetty, Shashirekha; Wang, Zhen; Rivera, Christine L; Portier, Bryce P; Budd, G Thomas; Downs-Kelly, Erinn; Lanigan, Christopher P; Calhoun, Benjamin C.

Afiliação

Donaldson AR; Department of Pathology, Robert J. Tomsich Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.
Shetty S; Department of Laboratory Medicine, Robert J. Tomsich Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.
Wang Z; Department of Pathology, Robert J. Tomsich Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.
Rivera CL; Department of Laboratory Medicine, Robert J. Tomsich Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.
Portier BP; Department of Pathology, Robert J. Tomsich Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.
Budd GT; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Downs-Kelly E; Department of Pathology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah.
Lanigan CP; Department of Pathology, Robert J. Tomsich Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.
Calhoun BC; Department of Pathology, Robert J. Tomsich Institute of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio.

Cancer ; 123(12): 2230-2239, 2017 Jun 15.

Article em En | MEDLINE | ID: mdl-28192599

Assuntos

Neoplasias da Mama/genética; Carcinoma/genética; Cromossomos Humanos Par 17/genética; Hibridização in Situ Fluorescente/métodos; Sondas Moleculares/genética; Receptor ErbB-2/genética; Antineoplásicos/uso terapêutico; Antineoplásicos Hormonais/uso terapêutico; Neoplasias da Mama/classificação; Neoplasias da Mama/tratamento farmacológico; Carcinoma/classificação; Carcinoma/tratamento farmacológico; Progressão da Doença; Feminino; Humanos; Oncologia; Terapia de Alvo Molecular; Recidiva Local de Neoplasia/epidemiologia; Patologia Clínica; Guias de Prática Clínica como Assunto; Estudos Retrospectivos

Palavras-chave

Erb-B2 receptor tyrosine kinase 2 (ERBB2); breast cancer; diagnosis; human epidermal growth factor receptor 2 (HER2); in situ hybridization; pathology; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cromossomos Humanos Par 17 / Neoplasias da Mama / Carcinoma / Sondas Moleculares / Hibridização in Situ Fluorescente / Receptor ErbB-2 Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google